Literature DB >> 15103687

Levels of urinary matrix metalloproteinase-9 (MMP-9) and renal injuries in patients with type 2 diabetic nephropathy.

Kyoichi Tashiro1, Ichiro Koyanagi, Ikko Ohara, Takamichi Ito, Akemi Saitoh, Satoshi Horikoshi, Yasuhiko Tomino.   

Abstract

To determine correlations among the levels of urinary MMP-9 and type-IV collagen, hyperglycemia, urinary protein excretion, and renal injuries in patients with type 2 diabetic nephropathy, we measured levels of urinary MMP-9 and protein, blood urea nitrogen (BUN), serum creatinine (s-Cr), fasting plasma glucose (FPG), and glycohemoglobin A1c (HbA1c) in 47 diabetic patients and 14 healthy adults. Urinary type-IV collagen was also measured in 28 diabetic patients and seven healthy adults. Patients with diabetic nephropathy were divided into two groups: 1). patients with normoalbuminuria or microalbuminuria (0-299 mg/g.Cr; n=27), and 2). patients with macroalbuminuria (>300 mg/g.Cr; n=20). The mean level of urinary MMP-9 in group 2 was significantly higher than those in healthy adults (P<0.05), and the levels of urinary MMP-9 in patients with diabetic nephropathy increased in accordance with the clinical stage of the disease. The levels of urinary MMP-9 tended to be correlated with HbA1c in these patients, but the correlation was not statistically significant. The mean level of urinary type-IV collagen in group 2 of patients with diabetic nephropathy was significantly higher than that in group 1 and healthy adults. Levels of urinary type-IV collagen in patients with diabetic nephropathy also increased in accordance with the clinical stage of the disease. The results suggest that measurements of urinary MMP-9, as well as urinary type-IV collagen, may be useful for evaluating the degree of renal injuries in patients with type 2 diabetic nephropathy, especially in the early stage. Copyright 2004 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15103687      PMCID: PMC6807695          DOI: 10.1002/jcla.20024

Source DB:  PubMed          Journal:  J Clin Lab Anal        ISSN: 0887-8013            Impact factor:   2.352


  11 in total

1.  Elevated matrix metalloproteinase-2 and -9 in urine, but not in serum, are markers of type 1 diabetic nephropathy.

Authors:  M Diamant; R Hanemaaijer; J H Verheijen; J W Smit; J K Radder; H H Lemkes
Journal:  Diabet Med       Date:  2001-05       Impact factor: 4.359

2.  Effect of glycated proteins on the matrix of glomerular epithelial cells.

Authors:  A K Singh; W Mo; G Dunea; J A Arruda
Journal:  J Am Soc Nephrol       Date:  1998-05       Impact factor: 10.121

3.  A one-step sandwich enzyme immunoassay for inactive precursor and complexed forms of human matrix metalloproteinase 9 (92 kDa gelatinase/type IV collagenase, gelatinase B) using monoclonal antibodies.

Authors:  N Fujimoto; N Hosokawa; K Iwata; T Shinya; Y Okada; T Hayakawa
Journal:  Clin Chim Acta       Date:  1994-11       Impact factor: 3.786

4.  Significance of urinary type IV collagen in patients with diabetic nephropathy using a highly sensitive one-step sandwich enzyme immunoassay.

Authors:  M Yagame; D Suzuki; K Jinde; N Saotome; H Sato; M Noguchi; H Sakai; T Kuramoto; K Sekizuka; T Iijima; S Suzuki; Y Tomino
Journal:  J Clin Lab Anal       Date:  1997       Impact factor: 2.352

5.  Increased mRNA expression of metalloproteinase-9 in peripheral blood monocytes from patients with immunoglobulin A nephropathy.

Authors:  H Koide; T Nakamura; I Ebihara; Y Tomino
Journal:  Am J Kidney Dis       Date:  1996-07       Impact factor: 8.860

6.  Down-regulation of glomerular matrix metalloproteinase-2 gene in human NIDDM.

Authors:  D Del Prete; F Anglani; M Forino; M Ceol; P Fioretto; R Nosadini; B Baggio; G Gambaro
Journal:  Diabetologia       Date:  1997-12       Impact factor: 10.122

7.  Glomerular distribution and gelatinolytic activity of matrix metalloproteinases in human glomerulonephritis.

Authors:  Maki Urushihara; Shoji Kagami; Takashi Kuhara; Toshiaki Tamaki; Yasuhiro Kuroda
Journal:  Nephrol Dial Transplant       Date:  2002-07       Impact factor: 5.992

8.  Increased plasma metalloproteinase-9 concentrations precede development of microalbuminuria in non-insulin-dependent diabetes mellitus.

Authors:  I Ebihara; T Nakamura; N Shimada; H Koide
Journal:  Am J Kidney Dis       Date:  1998-10       Impact factor: 8.860

9.  Follow-up study on urinary type IV collagen in patients with early stage diabetic nephropathy.

Authors:  T Iijima; S Suzuki; K Sekizuka; T Hishiki; M Yagame; K Jinde; N Saotome; D Suzuki; H Sakai; Y Tomino
Journal:  J Clin Lab Anal       Date:  1998       Impact factor: 2.352

10.  Changes in serum concentrations of matrix metalloproteinases, tissue inhibitors of metalloproteinases and type IV collagen in patients with various types of glomerulonephritis.

Authors:  K Akiyama; K Shikata; H Sugimoto; M Matsuda; Y Shikata; N Fujimoto; K Obata; H Matsui; H Makino
Journal:  Res Commun Mol Pathol Pharmacol       Date:  1997-02
View more
  23 in total

Review 1.  Matrix metalloproteinases, a disintegrin and metalloproteinases, and a disintegrin and metalloproteinases with thrombospondin motifs in non-neoplastic diseases.

Authors:  Takayuki Shiomi; Vincent Lemaître; Jeanine D'Armiento; Yasunori Okada
Journal:  Pathol Int       Date:  2010-07       Impact factor: 2.534

Review 2.  Regulated sodium transport in the renal connecting tubule (CNT) via the epithelial sodium channel (ENaC).

Authors:  Johannes Loffing; Christoph Korbmacher
Journal:  Pflugers Arch       Date:  2009-03-11       Impact factor: 3.657

Review 3.  Diabetic nephropathy and extracellular matrix.

Authors:  S O Kolset; F P Reinholt; T Jenssen
Journal:  J Histochem Cytochem       Date:  2012-10-27       Impact factor: 2.479

Review 4.  Protection of nitro-fatty acid against kidney diseases.

Authors:  Weidong Wang; Chunling Li; Tianxin Yang
Journal:  Am J Physiol Renal Physiol       Date:  2015-12-30

5.  Disease and gender-specific dysregulation of NGAL and MMP-9 in type 1 diabetes mellitus.

Authors:  Kathryn M Thrailkill; Cynthia S Moreau; Gael E Cockrell; Chan-Hee Jo; Robert C Bunn; Alba E Morales-Pozzo; Charles K Lumpkin; John L Fowlkes
Journal:  Endocrine       Date:  2010-01-12       Impact factor: 3.633

Review 6.  Matrix metalloproteinases in kidney homeostasis and diseases.

Authors:  Roderick J Tan; Youhua Liu
Journal:  Am J Physiol Renal Physiol       Date:  2012-04-04

7.  MMP-9- and NMDA receptor-mediated mechanism of diabetic renovascular remodeling and kidney dysfunction: hydrogen sulfide is a key modulator.

Authors:  Sourav Kundu; Sathnur Pushpakumar; Utpal Sen
Journal:  Nitric Oxide       Date:  2015-02-07       Impact factor: 4.427

Review 8.  A glimpse of matrix metalloproteinases in diabetic nephropathy.

Authors:  X Xu; L Xiao; P Xiao; S Yang; G Chen; F Liu; Y S Kanwar; L Sun
Journal:  Curr Med Chem       Date:  2014       Impact factor: 4.530

9.  Simvastatin protects diabetic rats against kidney injury through the suppression of renal matrix metalloproteinase-9 expression.

Authors:  X-M Yao; S-D Ye; Z Zai; Y Chen; X-C Li; G-W Yang; Y-X Wang; K Chen
Journal:  J Endocrinol Invest       Date:  2009-10-09       Impact factor: 4.256

Review 10.  Matrix metalloproteinases: their potential role in the pathogenesis of diabetic nephropathy.

Authors:  Kathryn M Thrailkill; R Clay Bunn; John L Fowlkes
Journal:  Endocrine       Date:  2008-10-30       Impact factor: 3.633

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.